Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13786517 | 0.88 | SCN9A (0.40) | SCN9ASCN5ASCN1ASCN2ASCN8A | |
| SCHEMBL13033295 | 0.86 | GCK (0.43) | GCK | |
| SCHEMBL3513379 | 0.86 | GCK (0.43) | GCK | |
| SCHEMBL3510001 | 0.85 | GCK (0.38) | SCN9AGCKKCNH2 | |
| SCHEMBL13144844 | 0.84 | KCNH2 (0.33) | GCKKCNH2 | |
| SCHEMBL13033314 | 0.84 | SCN9A (0.31) | SCN9AGCK | |
| SCHEMBL3509383 | 0.81 | GCK (0.44) | GCKKCNH2 | |
| SCHEMBL3511298 | 0.80 | SCN9A (0.31) | SCN9A | |
| SCHEMBL3510445 | 0.80 | — | — | |
| SCHEMBL13786525 | 0.80 | KCNH2 (0.46) | SCN9ASCN5AGCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| US-8329707-B2 | Substituted pyrazine compounds | ASTELLAS PHARMA INC. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100286171-A1 | PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2236498-A1 | PHENYL ACETAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286171-A1 | PHENYLACETAMIDE DERIVATIVE | AADAC, PGC, PC | SCN9A 1152/4885SCN5A 375/4885SCN1A 945/4885 |
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | PC, PCK2, GCKR | SCN9A 2623/4885SCN5A 973/4885SCN1A 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.